WVE News and Press, Wave Life Sciences Ltd. From 03/21/23

2023-03-21 11:46:42 ET Wave Life Sciences ( NASDAQ: WVE ) is scheduled to announce Q4 earnings results on Wednesday, March 22nd, before market open. The consensus EPS Estimate is -$0.41 (+32.8% Y/Y) and the consensus Revenue Estimate is $2.4M (+36.4% Y/Y). Over the las...

2023-03-13 04:02:42 ET In wake of the bank's collapse with turmoil surrounding Silicon Valley Bank, several smaller pharma, biotech companies and health care equipment have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). Among the biotec...

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference...

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive ...

Summary Wave Life Sciences caught a strong bid throughout the bulk of 2022, with the trend extending into the new year. Its novel hypothesis in Huntington's disease has piqued our interest most. It also signed a collaboration with GSK to advance its other pipeline assets. Market...

Summary Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading ...

Summary Two new Breakout Stocks for Week 52 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +139.4% YTD. This week 1 of 4 high frequency breakout picks gained over 10% in less than a week with peak gains in EDU +16.7%, while the...

53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology of WVE-N531 compared with Wave’s first-generation DMD program – demonstrated high muscle concentrations with a mean of 42 m...

Wave Life Sciences ( NASDAQ: WVE ) and GSK ( NYSE: GSK ) are collaborating to discover oligonucleotide therapeutics for novel genetic targets. Oligonucleotides are short strands of DNA or RNA which can reduce, restore, or modulate RNA through several different mechani...

Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave’s PRISM™ oligonucleotide platform and GSK’s expertise in genetics and genomics GSK to advance up ...